IP Verse

5-Methoxy-N,N-Dimethyltryptamine (5-Meo-Dmt) For Treating Depression - EP3927337

The patent EP3927337 was granted to GH Research on Mar 20, 2024. The application was originally filed on Feb 24, 2020 under application number EP20710059A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3927337

GH RESEARCH
Application Number
EP20710059A
Filing Date
Feb 24, 2020
Status
Granted And Under Opposition
Jan 12, 2024
Grant Date
Mar 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANNov 13, 2024CMS CAMERON MCKENNA NABARRO OLSWANGADMISSIBLE
PORTA SOPHIAMay 22, 2024FLEUCHAUS & GALLO PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0933093
DESCRIPTIONEP1884254
DESCRIPTIONUS7458374
DESCRIPTIONUS9370629
DESCRIPTIONUS9687487
INTERNATIONAL-SEARCH-REPORTWO2018195455
INTERNATIONAL-SEARCH-REPORTWO2019081764
OTHERWO2019081764

Non-Patent Literature (NPL) Citations (72) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BOGENSCHUTZ MP et al., "Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study", J Psychopharmacol., (20150000), vol. 29, no. 3, pages 289 - 99-
DESCRIPTION- BOGENSCHUTZ MP et al., "Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin", J Psychopharmacol., (20150000), vol. 29, no. 11, pages 1182 - 90-
DESCRIPTION- CARHART-HARRIS RL et al., "Neural correlates of the LSD experience revealed by multimodal neuroimaging", Proc Natl Acad Sci USA., (20160000), vol. 113, no. 17, pages 4853 - 8-
DESCRIPTION- CARHART-HARRIS RL et al., "Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms", Sci Rep., (20170000), vol. 7, no. 1, page 13187-
DESCRIPTION- CARHART-HARRIS RL et al., "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study", Lancet Psychiatry, (20160000), vol. 3, no. 7, pages 619 - 27-
DESCRIPTION- DAVIS AK et al., "The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption", J Psychopharmacol., (20180700), vol. 32, no. 7, pages 779 - 792-
DESCRIPTION- GARCIA-ROMEU A, "Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction", Curr Drug Abuse Rev., (20140000), vol. 7, no. 3, pages 157 - 64-
DESCRIPTION- GASSER P et al., "Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases", J Nerv Ment Dis., (20140000), vol. 202, no. 7, pages 513 - 20-
DESCRIPTION- JENSEN SE, "A treatment program for alcoholics in a mental hospital", Q J Stud Alcohol., (19620000), vol. 23, pages 315 - 20-
DESCRIPTION- JOHNSON MW et al., Am J Drug Alcohol Abuse., (20170000), vol. 43, no. 1, pages 55 - 60-
DESCRIPTION- JOHNSON MW et al., "Long-term follow-up of psilocybin-facilitated smoking cessation", Am J Drug Alcohol Abuse, (20170000), vol. 43, no. 1, pages 55 - 60-
DESCRIPTION- JOHNSON MW et al., "Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction", J Psychopharmacol., (20140000), vol. 28, no. 11, pages 983 - 92-
DESCRIPTION- "LSD-assisted psychotherapy with terminal cancer patients", PAHNKE WN et al., Psychedelic drugs. Proceedings of a Hahnemann Medical College and Hospital Symposium, Grune & Stratton, (19690000), pages 33 - 42-
DESCRIPTION- MACLEAN JR et al., "The use of LSD-25 in the treatment of alcoholism and other psychiatric problems", Q J Stud Alcohol., (19610000), vol. 22, pages 34 - 45-
DESCRIPTION- MORENO FA et al., "Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder", J Clin Psychiatry, (20060000), vol. 67, no. 11, pages 1735 - 40-
DESCRIPTION- PALHANO-FONTES F et al., "Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomised placebo-controlled trial", bioRxiv 103531, (20170000), URL: https://doi.org/10.1101/103531-
DESCRIPTION- PALHANO-FONTES F et al., "The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network", PLoS One, (20150000), vol. 10, no. 2, page e0118143-
DESCRIPTION- ROSEMAN L et al., "Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression", Front Pharmacol., (20180000), vol. 8, page 974-
DESCRIPTION- ROSS S et al., "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial", J Psychopharmacol., (20160000), vol. 30, no. 12, pages 1165 - 1180-
DESCRIPTION- UNGER SMMESCALINE, LSD, "Psilocybin, and Personality Change", Psychiatry, vol. 26, (19630000), pages 111 - 25, URL: https://erowid.org/chemicals/5meo_dmt/5meo_dmt_dose.shtml-
DESCRIPTION- CARHART-HARRIS RL et al., "Psilocybin with psychological support for treatment-resistant depression: six-month follow-up", Psychopharmacology (Berl, (20180000), vol. 235, no. 2, doi:10.1007/s00213-017-4771-x, pages 399 - 408, XP036477494
DESCRIPTION- GRIFFITHS RR et al., "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial", J Psychopharmacol., (20160000), vol. 30, no. 12, doi:10.1177/0269881116675513, pages 1181 - 1197, XP055611143
INTERNATIONAL-SEARCH-REPORT- CARHART-HARRIS R L ET AL, "Psilocybin with psychological support for treatment-resistant depression: six-month follow-up", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 235, no. 2, doi:10.1007/S00213-017-4771-X, ISSN 0033-3158, (20171108), pages 399 - 408, (20171108), XP036477494 [Y] 1-37 * abstract * * page 400, column 1, paragraph 1 *
INTERNATIONAL-SEARCH-REPORT- UTHAUG MALIN V ET AL, "Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 237, no. 3, doi:10.1007/S00213-019-05414-W, ISSN 0033-3158, (20191210), pages 773 - 785, (20191210), XP037030419 [T] * page 774, column 1, paragraph 3 - paragraph 5 * * page 783, column 1, line 2 * * page 777, column 1, paragraph 2 *
INTERNATIONAL-SEARCH-REPORT- GEYER M A ET AL, "Behavioural and pharmacological studies of pharmahuasca in rodents", EUROPEAN NEUROPSYCHOPHARMACOLOGY, (2016), vol. 26, doi:10.1016/S0924-977X(16)30889-6, ISSN 0924-977X, XP029787110 [A] 1-37 * examples 7-10 * * claims 9-12 *
INTERNATIONAL-SEARCH-REPORT- ALAN K. DAVIS ET AL, "5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety", AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, US, (20190301), vol. 45, no. 2, doi:10.1080/00952990.2018.1545024, ISSN 0095-2990, pages 161 - 169, XP055695498 [T] * abstract *
INTERNATIONAL-SEARCH-REPORT- SHEN HONG-WU ET AL, "Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice", vol. 39, no. 7, doi:10.1124/DMD.111.039107, ISSN 0090-9556, (20110630), pages 1227 - 1234, DRUG METABOLISM AND DISPOSITION, PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, URL: http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.111.039107, XP009520579 [Y] 10,11 * abstract *
INTERNATIONAL-SEARCH-REPORT- OSÓRIO FDE L ET AL, "Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report", REVISTA BRASILEIRA DE PSIQUIATRIA, PUBL. SOLUTIONS, BR, (20150101), vol. 37, no. 1, doi:10.1590/1516-4446-2014-1496, ISSN 1516-4446, pages 13 - 20, XP009520464 [X] 1-4,18,21,22 * page 15, column 2, paragraph 5 * * page 17 * * page 19, column 1, paragraph 2 - paragraph 4 *
INTERNATIONAL-SEARCH-REPORT- THOMAS G ET AL, "Ayahuasca-assisted therapyfor addiction: results from a preliminary observational study in Canada", CURRENT DRUG ABUSE REVIEWSE, BENTHAM SCIENCE PUBLISHERS LTD, (20130301), vol. 6, no. 1, doi:10.2174/15733998113099990003, ISSN 1874-4737, pages 30 - 42, XP009520465 [X] 1-4,18,21,22 * page 39, column 1, paragraph 3 - column 2, paragraph 1 *
OPPOSITION- Anonymous, "A phase 1/2 study of GH001 in patients with treatment-resistant depression", EU Clinical Trials Register; EudraCT Number: 2018-004208-20, EU Clinical Trials Register; EudraCT Number: 2018-004208-20, URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004208-20/NL, XP093242534-
OPPOSITION- Anonymous, "GH Research Announces Closing of $125 Million Oversubscribed Series B Financing", GH Research, GH Research, URL: https://investor.ghres.com/node/6906/pdf, XP093242469-
OPPOSITION- Anonymous, "Porta Sophia Publishes Narrative Review Manuscript Summarizing Historical Evidence of 5-MeO-DMT as a Compound Used in Therapeutic Practice ", Porta Sophia, Porta Sophia, URL: https://www.portasophia.org/newsroom/press-releases/porta-sophia-publishes-narrative-review-manuscript-summarizing-historical-evidence-of-5-meo-dmt-as-a-compound-used-in-therapeutic-practice-2, XP093242542-
OPPOSITION- Anonymous, " Seeking Ultra-Rapid, Durable Remissions in Depression", GH Research, GH Research, URL: https://investor.ghres.com/static-files/25e586e7-aaa1-4407-b4f5-e4881a4e9ff6, XP093242461-
OPPOSITION- Anonymous, " Seeking Ultra-Rapid, Durable Remissions in Depression", GH Research, GH Research, URL: https://investor.ghres.com/static-files/98982a00-067d-4bdd-8e03-73d3a83aa7ce, XP093242466-
OPPOSITION- Anonymous, "THE ESSENTIAL GUIDE TO 5-MEO-DMT", Third Wave (accessed via the Wayback Machine), Third Wave (accessed via the Wayback Machine), URL: https://web.archive.Org/web/20181109024846/https://thethirdwave.co/psychedelics/5-meo-dmt, XP093242471-
OPPOSITION- Anonymous, "What Is Depression?", American Psychiatric Association, (20190117), pages 1 - 6, American Psychiatric Association, URL: The Wayback Machine - https://web.archive.org/web/20190117034902/https://www.psychiatry.org/patient, (20240206), XP093127661-
OPPOSITION- Cowen P. L, "Altered states: psilocybin for treatment-resistant depression", The Lancet Psychiatry, (20160101), vol. 3, no. 7, pages 592 - 593, XP093178356-
OPPOSITION- D10 - Use of the terms “depression” and “treatment-resistant depression” by the Patentee in their public communications-
OPPOSITION- D12 - Corporate presentation from the Patentee dated May 2022-
OPPOSITION- D13 - Corporate presentation from the Patentee dated November 2022-
OPPOSITION- D15 - Corporate presentation from the Patentee dated May 2023-
OPPOSITION- D17 - Press release from the Patentee dated 3 September 2024-
OPPOSITION- D19 - Davis, AK & Lancelotta, R. (2018). The healing potential of 5-MeO- DMT: Results from two survey studies. Abstract of a presentation given in April 2018 at the Midwest Psychedelic Therapy Symposium, Madison Wisconsin-
OPPOSITION- D22 - EudraCT & EU CTR Question and Answer table, Frequently Asked Questions & Answers (FAQs) - V1.3 (March 2019).-
OPPOSITION- D28 - Form F-1 (Registration Statement Under Securities Act 1933) filed by GH Research PLC (of which GH Research is a subsidiary) with the Securities and Exchange Commission on 21 June 2021-
OPPOSITION- D29 - Communication under Article 94(3) on EP3927338 dated 12 December 2022-
OPPOSITION- D30 - Priority application of the Patent under Opposition.-
OPPOSITION- D38 - Meccia J, Casimir D, Li S, Shams S, Isenbarger TA, Seelig M. Treatment of major depressive disorder and treatment resistant depression with 5-MeO-DMT: impact of 25 years of non-traditional public scientific communication and education on clinical; no date to be found on paper-
OPPOSITION- D40 - Declaration of Mark Seelig-
OPPOSITION- Ewing C Greer, "Ground to Source- experiencing the Divine within - ", The Practical Tripper, (20170415), pages 1 - 10, The Practical Tripper, URL: https://thepracticaltripper.wordpress.com/2017/04/15/ground-to-source-experiencing-the-divine-within-2/, XP093190366-
OPPOSITION- Stafford, Peter, "Chapter 4: Psilocybian Mushrooms", Stafford, Peter, Stafford, Peter, Psychedelics Encyclopedia. (Third Edition), US, Ronin, (19930101), pages 224 - 279, ISBN 0-914171-51-8, XP009560863-
OPPOSITION- Stafford, Peter, "Chapter 6: DMT, DET, DPT and Other Short-Acting Tryptamines", Psychedelics Encyclopedia. (Third Edition), US, Ronin, (19990101), pages 309 - 331, ISBN 0-914171-51-8, XP009560864-
OPPOSITION- Howard G. Birnbaum; Ronald C. Kessler; David Kelley; Rym Ben‐Hamadi; Vijay N. Joish; Paul E. Greenberg, "Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance", DEPRESSION AND ANXIETY, NEW YORK, NY, US, US , (20090630), vol. 27, no. 1, doi:10.1002/da.20580, ISSN 1091-4269, pages 78 - 89, XP072005575
OPPOSITION- Quilty Lena C., Robinson Jennifer J., Rolland Jean‐pierre, Fruyt Filip De, Rouillon Frédéric, Bagby R. Michael, "The structure of the Montgomery-Åsberg depression rating scale over the course of treatment for depression", International Journal of Methods in Psychiatric Research, (20130901), vol. 22, no. 3, doi:10.1002/mpr.1388, ISSN 1049-8931, pages 175 - 184, XP093190368
OPPOSITION- Araújo Ana Margarida; Carvalho Félix; Bastos Maria de Lourdes; Guedes de Pinho Paula; Carvalho Márcia , "The hallucinogenic world of tryptamines: an updated review", Archives of Toxicology, SPRINGER, DE, DE , (20150416), vol. 89, no. 8, doi:10.1007/s00204-015-1513-x, ISSN 0340-5761, pages 1151 - 1173, XP035516380
OPPOSITION- Carhart-Harris R. L.; Bolstridge M.; Day C. M.; Rucker J.; Watts R.; Erritzoe D. E.; Kaelen M.; Giribaldi B.; Bloomfield M.; Pilling S.; Rickard J. A.; Forbes B.; Feilding A.; Taylor D.; Curran H. V.; Nutt D. J., "Psilocybin with psychological support for treatment-resistant depression: six-month follow-up", Psychopharmacology, SPRINGER VERLAG, BERLIN., DE, DE , (20171108), vol. 235, no. 2, doi:10.1007/s00213-017-4771-x, ISSN 0033-3158, pages 399 - 408, XP036415992
OPPOSITION- Kennett, G.A. ; Marcou, M. ; Dourish, C.T. ; Curzon, G., "Single administration of 5-HT"1"A agonists decreases 5-HT"1"A presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action", European Journal of Pharmacology, Elsevier science, NL, NL , (19870612), vol. 138, no. 1, doi:10.1016/0014-2999(87)90336-0, ISSN 0014-2999, pages 53 - 60, XP023751821
OPPOSITION- Kaufman Joshua; DeLorenzo Christine; Choudhury Sunia; Parsey Ramin V., "The 5-HT1Areceptor in Major Depressive Disorder", European Neuropsychopharmacology, Elsevier Sience Publishers BV , Amsterdam, NL, NL , (20160111), vol. 26, no. 3, doi:10.1016/j.euroneuro.2015.12.039, ISSN 0924-977X, pages 397 - 410, XP029457824
OPPOSITION- Riga Maurizio S.; Lladó-Pelfort Laia; Artigas Francesc; Celada Pau, "The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1Aand 5-HT2Areceptors", Neuropharmacology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19000101), vol. 142, doi:10.1016/j.neuropharm.2017.11.049, ISSN 0028-3908, pages 219 - 230, XP085542725
OPPOSITION- Dakic Vanja, Minardi Nascimento Juliana, Costa Sartore Rafaela, Maciel Renata De Moraes, De Araujo Draulio B., Ribeiro Sidarta, Martins-De-Souza Daniel, Rehen Stevens K., "Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT", Scientific Reports, Nature Publishing Group, US, US , vol. 7, no. 1, doi:10.1038/s41598-017-12779-5, ISSN 2045-2322, XP093242538
OPPOSITION- Carhart-Harris Robin L, Roseman Leor, Bolstridge Mark, Demetriou Lysia, Pannekoek J Nienke, Wall Matthew B, Tanner Mark, Kaelen Mendel, Mcgonigle John, Murphy Kevin, Leech Robert, Curran H Valerie, Nutt David J, "Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms", Scientific Reports, Nature Publishing Group, US, US , (20171013), vol. 7, no. 1, doi:10.1038/s41598-017-13282-7, ISSN 2045-2322, XP093189956
OPPOSITION- Alan K. Davis, So Sara, Lancelotta Rafael, Barsuglia Joseph P., Griffiths Roland R., "5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety", AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, MARCEL DEKKER, NEW YORK,NY,, US, US , (20190304), vol. 45, no. 2, doi:10.1080/00952990.2018.1545024, ISSN 0095-2990, pages 161 - 169, XP055695498
OPPOSITION- Shen Hong-Wu; Jiang Xi-Ling; Yu Ai-Ming SUNY Buffalo, Sch Pharm and Pharmaceut Sci, Dept Pharmaceut Sci, 541 Cooke Hall, Buffalo, NY 14260 USA; [email protected], "Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice", Drug Metabolism and Disposition, Pharmacology and Experimental Therapeutics, US, US , (20110630), vol. 39, no. 7, doi:10.1124/dmd.111.039107, ISSN 0090-9556, pages 1227 - 1234, XP009520579
OPPOSITION- Alan K Davis, Joseph P Barsuglia, Rafael Lancelotta, Robert M Grant, Elise Renn, "The epidemiology of 5-methoxy- N, N -dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption", JOURNAL OF PSYCHOPHARMACOLOGY., OXFORD UNIVERSITY PRESS., GB, GB , (20180701), vol. 32, no. 7, doi:10.1177/0269881118769063, ISSN 0269-8811, pages 779 - 792, XP009556070
OPPOSITION- Jaffe Dena H., Rive Benoit, Denee Tom R., "The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study", BMC PSYCHIATRY, BIOMED CENTRAL, LONDON, GB, GB , (20191201), vol. 19, no. 1, doi:10.1186/s12888-019-2222-4, ISSN 1471-244X, pages 1 - 11, XP093127705
OPPOSITION- Malhi Gin S., Das Pritha, Mannie Zola, Irwin Lauren, "Treatment-resistant depression: problematic illness or a problem in our approach?", British Journal of Psychiatry, The, Royal College of Psychiatrists, (20190101), vol. 214, no. 1, doi:10.1192/bjp.2018.246, ISSN 0007-1250, pages 1 - 3, XP093127711
OPPOSITION- Lima da Cruz Rafael Vitor; Moulin Thiago C; Petiz Lyvia Lintzmaier; Leao Richardson N, "A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus", Frontiers in molecular neuroscience, Frontiers Research Foundation, CH, CH , (20180904), vol. 11, doi:10.3389/fnmol.2018.00312, ISSN 1662-5099, pages Art. 312, 1 - 11, XP009520556
OPPOSITION- Leor Roseman, David J. Nutt, Robin L. Carhart-Harris, "Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression", Frontiers in Pharmacology, vol. 8, doi:10.3389/fphar.2017.00974, XP055707475
OPPOSITION- Joseph Barsuglia, Alan K. Davis, Robert Palmer, Rafael Lancelotta, Austin-Marley Windham-Herman, Kristel Peterson, Martin Polanco, Robert Grant, Roland R. Griffiths, "Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study", Frontiers in Psychology, Frontiers Research Foundation, vol. 9, doi:10.3389/fpsyg.2018.02459, ISSN 1664-1078, pages 1 - 6, XP055695516
OPPOSITION- Reckweg Johannes T., Van Leeuwen Cees J., Henquet Cécile, Van Amelsvoort Therese, Theunissen Eef L., Mason Natasha L., Paci Riccardo, Terwey Theis H., Ramaekers Johannes G., "A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression", Frontiers in Psychiatry, Frontiers Media SA, Frontiers in psychiatrySwitzerland2020, Frontiers in psychiatrySwitzerland2020, (20230620), vol. 14, doi:10.3389/fpsyt.2023.1133414, ISSN 1664-0640, XP093182606
OTHER- Barrett Frederick S, Johnson Matthew W, Griffiths Roland R, "Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin", JOURNAL OF PSYCHOPHARMACOLOGY., OXFORD UNIVERSITY PRESS., GB, GB , (20151101), vol. 29, no. 11, doi:10.1177/0269881115609019, ISSN 0269-8811, pages 1182 - 1190, XP055947322
OTHER- Alan K Davis, Joseph P Barsuglia, Rafael Lancelotta, Robert M Grant, Elise Renn, "The epidemiology of 5-methoxy- N, N -dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption", JOURNAL OF PSYCHOPHARMACOLOGY., OXFORD UNIVERSITY PRESS., GB, GB , (20180701), vol. 32, no. 7, doi:10.1177/0269881118769063, ISSN 0269-8811, pages 779 - 792, XP055695664

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents